Lexicon Pharmaceuticals, Inc.
LXRX
$0.3918
$0.02416.55%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.75M | 1.65M | 1.13M | 702.00K | 162.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.75M | 1.65M | 1.13M | 702.00K | 162.00K |
| Cost of Revenue | 25.85M | 17.81M | 14.40M | 14.83M | 17.57M |
| Gross Profit | -24.10M | -16.16M | -13.27M | -14.13M | -17.40M |
| SG&A Expenses | 39.59M | 39.19M | 32.06M | 32.61M | 32.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.44M | 57.00M | 46.46M | 47.44M | 49.79M |
| Operating Income | -63.69M | -55.35M | -45.33M | -46.74M | -49.63M |
| Income Before Tax | -64.81M | -53.43M | -48.40M | -49.76M | -50.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -64.81M | -53.43M | -48.40M | -49.76M | -50.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.81M | -53.43M | -48.40M | -49.76M | -50.53M |
| EBIT | -63.69M | -55.35M | -45.33M | -46.74M | -49.63M |
| EBITDA | -63.57M | -55.22M | -45.19M | -46.59M | -49.48M |
| EPS Basic | -0.18 | -0.17 | -0.20 | -0.20 | -0.21 |
| Normalized Basic EPS | -0.11 | -0.11 | -0.12 | -0.13 | -0.13 |
| EPS Diluted | -0.18 | -0.17 | -0.20 | -0.20 | -0.21 |
| Normalized Diluted EPS | -0.11 | -0.11 | -0.12 | -0.13 | -0.13 |
| Average Basic Shares Outstanding | 361.49M | 310.84M | 245.39M | 244.93M | 244.93M |
| Average Diluted Shares Outstanding | 361.49M | 310.84M | 245.39M | 244.93M | 244.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
